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The transcription factor NF-E2 related factor 2 (Nrf2) is ubiquitously expressed and a master 
regulator of antioxidant, phase II and proteostatic genes induced by oxidative or electrophilic 
stress (1; 2). Basally, Nrf2 is continually synthesized and associates with adaptor protein 
Kelch-like ECH Associated Protein 1 (Keap1), resulting in its ubiquitination and rapid 
degradation via the 26S proteasome (3-5). Following oxidative challenge, modification of key 
cysteine residues on Keap1 prevent Nrf2 degradation, allowing de novo Nrf2 to translocate to 
the nucleus and initiate transcription of target genes containing an antioxidant or electrophilic 
response element (ARE/EpRE) in their promoter region. In cells, failure to activate Nrf2 
defenses increases their susceptibility to oxidative damage and dysfunction, contributing to 
the pathogenesis of various cardiometabolic disease states including hypertension, 
cardiomyopathy, gestational and/or Type II diabetes (6-8).  
In this issue of Diabetes (9), Lu et al. demonstrate a novel role for Nrf2 in the regulation of the 
large conductance Ca2+-activated K+ (BK) channel-β1 subunit. As with other recently identified 
Nrf2-regulated solute transporters, this channel has no intrinsic antioxidant activity but is 
nevertheless important in homeostatic control of cell function. BK channels are expressed on 
vascular endothelial and smooth muscle cells (SMCs) and consist of a tetramer of α subunits, 
containing a channel pore domain, voltage sensor and Ca2+-sensing region. These α subunits 
are each associated with a tissue-specific modulatory β subunit (isoforms β1-4), altering 
channel activity (10). The β1 subunit is abundantly expressed in vascular SMCs and enhances 
the BK channels sensitivity to Ca2+ (11). Activation of BK channels leads to K+ efflux, resulting 
in membrane hyperpolarization and inhibition of Ca2+ influx through large conductance L-type 
Ca2+ channels, allowing BK channels to sense and modulate intracellular Ca2+ levels.  
In the current study, Lu et al. (9) used a mouse model of high fat diet (HFD) to induce 
hypertension and insulin resistance. They showed that in HFD mice, diminished Nrf2 
expression correlates with a 57% reduction in BK-β1 subunit protein expression. The authors 
also report that reduced BK-β1 subunit expression coincides with reduced BK channel 
excitability in patch-clamped single coronary artery SMCs treated with the BK-β1 activator 
DHS-1. Raised mean arterial pressure (MAP) (HFD 105.2±3.7 vs. lean 91.9±4.8 mmHg) and 
impaired BK-β1 dependent vasodilation of coronary arteries reported by Lu et al. are 
consistent with previous studies supporting a role for BK-β1 in mediating vasodilation and 
contributing towards the regulation of myogenic tone and sympathetically mediated MAP.  
 
Previously, deletion of the BK-β1 subunit in mice was shown to uncouple transient Ca2+ 
release from intracellular stores (Ca2+ sparks) to BK channel activation, raising MAP (12; 13) 
with primarily night-time MAP corresponding to peak activity and enhanced sympathetic 
outflow affected (14). Diminished BK-β1 expression and Ca2+ sensitivity are also observed in 
rat models of genetic hypertension (WKY and SHR) (15) and angiotensin II induced 
hypertension(11). In humans, few studies have explored the contribution of BK-β1 in vascular 
function, but do indicate BK-β1 may be a useful therapeutic target for cardiometabolic disease 
prevention.  
 
Previous studies demonstrate and autoregulatory role for BK channels, with blockade of BK 
channels using IBTX reducing vasodilation in response to increased intraluminal pressure in 
isolated human skeletal muscle arterioles (16). A common polymorphism in the gene 
encoding the BK-β1 subunit (E65K genotype) results in augmented Ca2+ sensitivity of BK 
channels and is associated with a lower incidence of diastolic hypertension in humans (17). 
Interestingly, the frequency of this polymorphism and its negative association with diastolic 
hypertension appears greatest in female participants over the age of 55 (18). The underlying 
mechanism(s) responsible for age and sex-specific differences in BK channel activation are at 
this stage unclear. Ovariectomy does not alter BK channel expression (19), nor does E65K alter 
in vitro BK channel activation in response to 17-β estradiol (18), an established activator of BK 
channels (20). In aged male rodents, BK channel α and β1 subunit expression declines (21) 
and oxidation of BK-α subunit Cys911 reduces the sensitivity of BK channels to Ca2+, reducing 
channel activation (22). It is therefore conceivable that a pro-oxidative environment found 
during aging, or as in the present HFD study cardiometabolic disease, may be needed to fully 
dissect the contribution of BK-β1 to blood pressure in male and female cohorts.  
 
Highlighting the influence of redox-regulated transcription on BK-β1 expression, the present 
study by Lu et al. demonstrates that Nrf2 attenuates the expression of the muscle specific E3 
ubiquitin ligase MuRF1 by inhibiting pro-oxidant transcription factor NFκB. Using pull-down 
assays, this group has previously characterized a direct interaction between MuRF1 and the 
BK-β1 subunit, with silencing of MuRF1 or inhibition of proteasomal degradation leading to 
BK-β1 stabilization and enhanced BK channel activity in a Type 1 diabetic mouse model (23). 
Whilst direct interaction of MuRF1 with BK-β1 strongly suggests enhanced proteolysis does 
indeed contribute to reduced BK-β1 expression in diabetes, inhibition of global proteasomal 
activity to prevent BK-β1 degradation, as used in this study, will produce off-target effects 
including the stabilisation of Nrf2. Future studies genetically ablating the BK-β1-MuRF1 
binding site or pulse-chase analysis of BK-β1 protein degradation may provide more definitive 
evidence for the functional importance of this interaction.   
 
Excitingly the current study provides strong evidence that induction of Nrf2 can restore BK-
β1 expression and activity both in vitro and in vivo. To establish that Nrf2 regulates BK-β1 
expression, the authors transfected cultured SMCs with Nrf2 overexpressing and silencing 
adenoviruses.  They showed clearly that enhanced Nrf2 levels result in increased expression 
of BK-β1 mRNA and protein and that suppression of Nrf2 expression reduces BK-β1 
levels.  These findings suggest that Nrf2’s effect on BK-β1 levels are at least partly exerted 
through transcriptional regulation, consistent with the authors’ description of a Nrf2 ARE 
consensus sequence in the BK-β1 promoter. Further studies are required to resolve the 
relative contribution of NFκB mediated BK-β1 proteolysis versus Nrf2 dependent 
transcriptional upregulation of BK-β1. Perhaps the most convincing evidence underpinning a 
potential therapeutic role of Nrf2 in stabilizing BK-β1 is the restoration of BK-β1 expression 
following 10-day administration of FDA-approved Nrf2 activator DMF in HFD treated mice. 
Acute treatment of human SMCs with DMF confirms upregulation of BK-β1 mRNA and 
protein, providing further evidence that BK-β1 is a newly identified Nrf2 target gene (see Fig. 
1). 
 
Whilst Nrf2 is capable of inducing BK-β1 subunit expression, the observation that basal BK-β1 
subunit mRNA expression is stable despite lower Nrf2 protein expression suggests other 
transcriptional regulators regulate BK-β1 expression and strongly warrant further 
investigation. Moreover, as both Nrf2 and BK-β1 expression and activity appear to be 
sensitive to both reactive oxygen species and O2 tension (22; 24; 25), conducting further in 
vitro studies under a physiological O2 levels may provide valuable insights into BK channel 
modulation in physiological and pathological settings, allowing age and sex associated 
differences in BK activity to be explored and the efficacy of BK-β1 induction to treat various 
vasculopathies assessed.  
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Fig. 1 Proposed transcriptional and non-transcription regulation of BK-β1 by Nrf2 
1. Large conductance Ca2+-activated K+ (BK) channels become activated in response to a rise 
in intracellular Ca2+, with the β1 subunit (expressed in smooth muscle cells) increasing channel 
sensitivity to Ca2+. K+ extrusion leads to membrane hyperpolarization, promoting inhibition of 
voltage dependent Ca2+ channels (VDCC) such as large conductance L-type Ca2+ channels, 
thereby preventing contraction. BK α and β subunit expression and/or activity can be further 
modulated by aging, oxidative stress induced BK-α Cys911 oxidation or O2 tension. 2. DMF 
relieves Keap1-mediated repression of Nrf2, allowing Nrf2 nuclear accumulation and 
induction of newly identified target gene BK-β1. 3. Nrf2 also attenuates NFκB stabilization, 
reducing MuRF1 expression and consequently ubiquitination and degradation of BK-β1 via 
the 26S proteasome.  
 
